FDA approves Ibrance maintenance combo for HR-positive, HER2-positive metastatic breast cancer

FDA has approved Ibrance (palbociclib) in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for maintenance treatment of adults with HR-positive, HER2-positive locally advanced or metastatic breast cancer following induction treatment.

The approval adds a CDK4/6 inhibitor to maintenance therapy for patients whose disease has not progressed after induction treatment with a taxane and HER2-directed therapy. For clinicians, the decision point is after initial disease control, when ongoing HER2-targeted therapy and endocrine therapy are commonly used to maintain response and delay progression.

Palbociclib is already widely used in HR-positive, HER2-negative advanced breast cancer. This approval extends its role to a biologically distinct population with dual hormone receptor and HER2-positive disease, where both endocrine signaling and HER2 signaling may contribute to ongoing tumor growth.

FDA based the approval on PATINA, a randomized, open-label trial of 518 patients with HR-positive, HER2-positive locally advanced or metastatic breast cancer who had no evidence of progression after induction treatment with a taxane and trastuzumab, with or without pertuzumab, for advanced disease.

Patients were randomly assigned to receive palbociclib plus trastuzumab, with or without pertuzumab, and endocrine therapy, or trastuzumab, with or without pertuzumab, and endocrine therapy alone. Endocrine therapy consisted of fulvestrant or an aromatase inhibitor, including anastrozole, letrozole, or exemestane.

Palbociclib-based maintenance therapy significantly improved investigator-assessed progression-free survival compared with HER2-directed therapy and endocrine therapy alone. The hazard ratio for disease progression or death was 0.76, corresponding to a 24% relative reduction in risk. The analysis showed a progression-free survival benefit, but follow-up was not yet long enough to determine whether overall survival also improved.

Warnings and precautions in the Ibrance prescribing information include neutropenia, interstitial lung disease/pneumonitis, and embryo-fetal toxicity.

Palbociclib received breakthrough therapy designation for this indication, reflecting the need for additional options in this maintenance setting. The approval gives clinicians a new way to extend disease control after induction therapy in HR-positive, HER2-positive metastatic breast cancer.

Source: Food and Drug Administration. 2026 June 24. [Press release]. FDA approves palbociclib with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of HR-positive, HER2-positive metastatic breast cancer